We retrospectively reviewed lung cancer patients who were treated with stereotactic ablative radiotherapy (SABR). We investigated the value of response evaluation after treatment by measuring the volume change of tumors on serial chest computed tomography (CT) examinations. The study included 11 consecutive patients with early-stage (T1-T2aN0M0) non-small cell lung cancer (NSCLC) who were treated with SABR. The median dose of SABR was 6,000 cGy (range 5,000∼6,400) in five fractions. Sequential follow-up was performed with chest CT scans. Median follow-up time was 28 months. Radiologic measurement was performed on 51 CT scans with a median of 3 CT scans per patient. The median time to partial response (TPR) was 3 months and median time to complete remission (TCR) was 5 months. Overall response rate was 90.9% (10/11). Five patients had complete remission, five had partial response, and one patient developed progressive disease without response. On follow-up, three patients (27.2%) developed progressive disease after treatment. We evaluated the the response after SABR. Our data also showed the timing of response after SABR.
Introduction
During the past decade, the standard therapy for operable, early-stage (T1-T2aN0M0), non-small cell lung cancer (NSCLC) has been lobectomy. 1) Conventionally fractionated radiotherapy for patients with early-stage NSCLC who are medically inoperable has traditionally been regarded as superior to no treatment but not able to achieve levels of local control (LC) or overall survival (OS) similar to those of surgical resection.
During the past decade, stereotactic ablative radiotherapy (SABR; also called stereotactic body radiotherapy) has become standard of care for patients with early-stage NSCLC who are clinically unable to tolerate a surgical procedure or refuse surgery. SABR has resulted in LC in excess of 90% for tumors that are medically inoperable and operable tumors in clinical stage INSCLC [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and overall survival after SABR was better than that achieved after conventional fractionated radiotherapy. 14 We investigated the value of response evaluation after treatment by measuring the size change of tumors on serial chest CT examinations. Table 1 .
The most common primary tumour histology was squamous cell carcinoma (54.5%). Median tumor size was 26 mm (range: 15∼46).
Treatment
The patients underwent 4DCT scans for treatment planning.
The 4DCT images were obtained using a 4DCT scanner (Light The SABR dose was prescribed to deliver 100% of the prescribed dose to ＞99% of the ITV and 95% of the prescribed dose to ＞99% of the PTV. The PTV consisted of the ITV plus a 5 mm margin uniformly. The treatment dose schedule is shown in Table 2 .
Post-SABR follow-up consisted of contrast enhanced CT scans of the thorax and PET-CT. Sequential follow-up was performed in our institution. Time-to-event outcomes were analyzed.
Response criteria
For 2-dimensional (2D) measurement, the tumor mass in the axial plane of the CT scan was measured at the longest cross-sectional diameter and the longest diameter perpendicular to it. Response criteria were defined as follows: complete response (CR), complete resolution; partial response (PR), decrease of at least 30%; progressive disease (PD), increase of at least 20%; and stable disease (SD), neither PR nor PD.
Fisher's exact test was performed to examine the influence of variables on response.
Results

Radiologic tumor size change
Over a median follow-up of 28 months (range, 2∼50 months), the 3-year overall survival rate of all 11 patients was 80.0% (Fig. 1) . Radiologic measurement was performed on 51
CT scans (11 pre-radiotherapy and 40 post-SABR CT scans) with a median number of 3 CT scans per patient. For all 11 patients, the mean pre-RT maximum diameter of tumor was 29 mm. Detailed RT-related parameters are listed in Table 2 .
The relative values of the maximum diameter of the tumor on follow-up CT scans with reference to pre-SABR values were obtained. The median time to partial response (TPR) was 3 months and median time to complete remission (TCR) was 5 months.
Response rates and patterns of failure
The response rates (RRs) are listed in Table 3 . Overall RR measured by the 2D-method was 90.9% (10 of 11 patients).
Five patients had CR, five had PR, and one developed progressive disease without response.
Three patients (27.2%) developed progressive disease after treatment. Among the three patients with progression, two (18.2%) had in-field failure with metastatic nodules and one (9.1%) had local failure with regional lymph node metastasis.
Patients with higher-stage disease tended to undergo recurrence more frequently with disease progression, but the difference was not statistically significant (p=0.490).
Discussion
Many studies have shown that stereotactic ablative radiotherapy (SABR) is effective for the treatment of early-stage non-small cell lung cancer and SABR has become the standard of care for medically inoperable NSCLC. With a median follow-up of 27.5 months, 3-year local control rates were 84.33% and there was no grade 3 toxicity. 17) In our study, the median follow-up was 28 months (range, 2∼50 months), overall survival rate was 80.0%. T-stage did not
show as an independent predictor of overall survival. After SABR, the initial response rate to treatment was 81.8%. Table   3 lists the response rates (RRs). The overall response rate was 90.9% and 5 of 11 (45.4%) patients had complete remission of the tumor.
The patients treated with SABR in our study experienced few toxicities. One patient experienced a rib fracture (grade The median time to progression of disease was 10.5 months.
Three patients (27%) had local failure with metastatic nodules and one patient (9%) had local failure with regional lymph node metastasis. Only one patient showed a PD response at the initial CT scan. The mean number of CT scans performed after SABR was 3.6 and the median time of the first CT scan from the end of treatment was 1 month (range, 1∼6).
There are some limitations associated with the nature of this study, which was a single-institutional retrospective study with a small number of enrolled patients with SABR treatment.
Conclusion
The overall response rate after SABR was 90.9%. Our data suggest that some patients could have a response as early as 1 month after RT. In addition, we evaluated the timing of the response after SABR. Our results may help clinicians with treatment planning for patients with early-stage non-small cell lung cancer.
